Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Teleflex (TFX) Q4 Earnings Miss Estimates, Margins Rise

by Zacks Equity Research

In Q4, Teleflex (TFX) registers strong growth in PICC, visual navigation products and EZ-IO.

Stryker Expands Acquisition Portfolio With Arrinex Buyout

by Zacks Equity Research

Stryker's (SYK) latest buyout is expected to boost its Neurotechnology & Spine business.

CVS Health Rides on Aetna Synergy, PBM Selling Season Modest

by Zacks Equity Research

With regard to its 2019 PBM selling season, CVS Health (CVS) notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds.

Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls

by Zacks Equity Research

Chemed's (CHE) Q4 revenues grow across key segments.

Quest Diagnostics Grows on Innovation Amid Reimbursement Woe

by Zacks Equity Research

Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.

Why Is Abbott (ABT) Up 6% Since Last Earnings Report?

by Zacks Equity Research

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Hold DaVita (DVA) Stock Now

by Zacks Equity Research

DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.

NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

NuVasive (NUVA) reports growth in revenues across all key operating segments in the fourth quarter of 2018.

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed at $75.14 in the latest trading session, marking a -0.53% move from the prior day.

Medidata's (MDSO) Margins Under Pressure, Competition Rife

by Zacks Equity Research

Medidata (MDSO) suffers from cutthroat competition in the clinical trial solutions market at the moment.

CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up

by Zacks Equity Research

CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.

Intuitive Surgical Gets FDA Nod for Ion Endoluminal System

by Zacks Equity Research

The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.

Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down

by Zacks Equity Research

Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.

Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose

by Zacks Equity Research

The favorable PRODIGY study result by Medtronic (MDT) is undoubtedly a timely, strategic finding.

Here's Why Investors Should Buy Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.

Align Technology Unveils iTero Element 5D Imaging System

by Zacks Equity Research

Align Technology (ALGN) continues to expand work flow options of iTero scanners.

Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4

by Zacks Equity Research

Cryolife (CRY) revenues increase year over year across all geographies and major segments.

Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock

by Zacks Equity Research

Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.

Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B

by Zacks Equity Research

Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.

Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

by Zacks Equity Research

In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

Baxter's Acute Therapies Profile Strong, Competition Rife

by Zacks Equity Research

Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.

Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines

by Zacks Equity Research

Bio-Techne (TECH) sees increase in revenues across key segments.

Boston Scientific Benefits From New Buyouts & Product Launch

by Zacks Equity Research

Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.

Here's Why Investors Should Retain AmerisourceBergen Stock

by Zacks Equity Research

AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.

Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm

by Zacks Equity Research

The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.